Loading...
NEJM Group was on hand to cover the 2024 American Society of Hematology (ASH) annual meeting, held December 7 to 10 in San Diego. Here, NEJM Journal Watch Oncology and Hematology reports some of the key findings in hematologic malignancies, and Associate Editor Dr. Michael E. Williams provides clinical perspective.
In patients with relapsed or refractory follicular lymphoma, the addition of tafasitamab to lenalidomide plus rituximab improves progression-free survival (PFS), according to the industry-funded, phase 3 inMIND trial. Tafasitamab, a humanized CD19-targeting monoclonal antibody, is currently approved in combination with lenalidomide for the treatment of relapse…